The GCC2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the GCC2 gene in the human Raji B lymphocyte cell line. This product provides a robust loss-of-function model for investigating the cellular and molecular roles of GCC2 without clonal isolation, preserving the heterogeneous genetic background of the parental line.
Raji cells are an Epstein-Barr virus (EBV)-positive Burkitt lymphoma-derived suspension cell line, widely utilized as a model for B-cell biology and lymphomagenesis. They retain key features of germinal center B cells, including the capacity for antibody production and MHC class II-mediated antigen presentation, making them suitable for studying humoral immunity and B-cell receptor signaling.
The GCC2 gene encodes GCC185, a large coiled-coil protein that localizes to the trans-Golgi network (TGN) and acts as a tethering factor for retrograde transport vesicles from endosomes. GCC185 interacts directly with the small GTPases RAB9A and RAB6A, the ARF-like protein ARL1, and the adaptor TBC1D23, forming a complex that captures COPI-coated vesicles and mediates their fusion with the TGN. This process is essential for maintaining Golgi ribbon integrity, retrograde trafficking of TGN-resident proteins such as TGN46, and the proper localization of Golgi enzymes. Disruption of GCC2 consequently impairs endosome-to-TGN retrograde trafficking and COPI-mediated transport, leading to altered Golgi morphology and mislocalization of downstream effectors.
In the Raji B-cell context, GCC2 function is particularly relevant to antibody secretion and surface receptor dynamics. The endosome-to-TGN pathway is critical for recycling of B-cell receptors and efficient delivery of immunoglobulins to the cell surface. Loss of GCC185-mediated tethering may disrupt these processes, potentially affecting humoral immune responses and contributing to B-cell malignancy phenotypes. Therefore, this knockout model offers a valuable tool for dissecting Golgi-dependent mechanisms in Burkitt lymphoma and other B-cell malignancies.
Researchers can employ this polyclonal knockout population in a wide range of experiments, including immunofluorescence staining for Golgi markers (e.g., GM130, TGN46) to assess morphological changes, Western blotting and RT-qPCR for confirmation of GCC2 disruption, and functional assays such as ELISA to measure secreted antibodies. Confocal microscopy enables detailed visualization of Golgi ribbon fragmentation, while flow cytometry can quantify surface expression of B-cell receptors. These applications support drug screening efforts targeting Golgi-related vulnerabilities in lymphoma. For additional information or technical inquiries, please contact Ascent Research.
